Tag archive for ‘Addressable market for Palforzia’
Aimmune Therapeutics: (AIMT, $23.63) Palforzia for Peanut Allergy Desensitization Has the Potential to Be a Blockbuster
Introduction Aimmune is the first company for some time on which I have picked up coverage. My screening criteria is not rigid, but I generally look for a company with a unique late stage product that has great commercial potential and has a solid financial (cash) position. Aimmune Therapeutics with Palforzia for desensitization of patients […]